Efficacy of Megadose Vitamin C in Severe and Critical Ill COVID-19 Patients.
Status:
Recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
The main aim is to determine whether vitamin C can reduce 28-day all-cause mortality or
persistent organ dysfunction compared with placebo in patients with severe and critical ill
COVID-19 patients.
Participants will randomly receive HIVC or placebo for 4 days once enrolled. The primary
outcome is a composite of death or persistent organ dysfunction (defined as dependency on
vasopressors, mechanical ventilation, or CRRT) at day 28 after randomization.